RT Journal Article
SR Electronic
T1 Seroepidemiology of human leptospirosis in the Dominican Republic: a multistage cluster survey, 2021
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.19.24312221
DO 10.1101/2024.08.19.24312221
A1 Nilles, Eric J.
A1 Paulino, Cecilia Then
A1 Galloway, Renee
A1 Aubin, Michael de St.
A1 Mayfield, Helen J.
A1 Restrepo, Angela Cadavid
A1 Dumas, Devan
A1 Garnier, Salome
A1 Etienne, Marie Caroline
A1 Duke, William
A1 Peña, Farah
A1 Iihoshi, Naomi
A1 Abdalla, Gabriela
A1 Lopez, Beatriz
A1 de la Cruz, Lucia
A1 Henríquez, Bernarda
A1 Durski, Kara
A1 Baldwin, Margaret
A1 Loevinsohn, Gideon
A1 Rees, Eleanor M.
A1 Martin, Beatris
A1 Sartorius, Benn
A1 Skewes-Ramm, Ronald
A1 Gutiérrez, Emily Zielinski
A1 Kucharski, Adam
A1 Lau, Colleen L.
YR 2024
UL http://medrxiv.org/content/early/2024/08/20/2024.08.19.24312221.abstract
AB Little is known about the epidemiology of leptospirosis in the Dominican Republic, the second most populous country in the Caribbean. We report on findings from a multi-stage household survey across two regions in the country that reveals a previously under-estimated burden of human Leptospira infection. Our findings, based on the reference-standard microscopic agglutination test, indicate a complex picture of serogroup diversity, spatial heterogeneity in infection and risk, and a marked discrepancy between reported cases and serologically estimated infections. Given an overall seroprevalence of 11.3% (95% CI: 10.8-13.0%) and a lower estimated force of infection (0.30% per year [0.27% - 0.35%]) the number of infections may exceed national reported case data by 145-fold or more. Icterohaemorrhagiae, associated with severe Weil’s disease, was the most commonly identified serogroup with a serogroup-specific prevalence of 4.4%. Consistent with other settings, risk factors including age, male sex, and rat exposure were associated with higher seroprevalence. Our study highlights the need for targeted public health interventions informed by serogroup-specific dynamics, detailed spatial analyses, knowledge of local animal reservoirs, and strengthened laboratory surveillance to effectively control this pathogen.Competing Interest StatementE.J.N. is the PI on a US CDC funded U01 award that funded the study, and C.L.L., A.K., D.D., M.d.S.A., A.C.R., H.M., S.G., M.C.E., W.D., N.I., G.A., B.H., K.D., M.B. have received salaries, consultancy fees, or travel paid through this award. E.Z.G., B.L. are employees of the US CDC. B.H., C.T., L.C., F.P., and R.S.-R. are employees of the Ministry of Ministry of Health and Social Assistance, Dominican Republic, that was subcontracted with funds from the US CDC award. A.K is supported by the Wellcome Trust, UK. CLL is supported by the Australian National Health and Medical Research Council. CDC staff supported the design and manuscript editing. We declare no other competing interests.Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study protocol was approved by the National Council of Bioethics in Health, Santo Domingo (013-2019), the Institutional Review Board of Pedro Henríquez Ureña National University, Santo Domingo, and the Mass General Brigham Human Research Committee, Boston, USA (2019P000094).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesA complete de-identified dataset and R code are available at [placeholder] for the purpose of reproducing and building on the analyses.